What is Bio-Sourcing?
Bio-Sourcing is a biotechnology firm specializing in the development of a novel, sustainable, and profitable platform for producing next-generation biotherapeutics, particularly monoclonal antibodies. The company leverages advanced technology, including genome editing and nuclear transfer, to facilitate the production of these vital medical compounds within goat's milk. This unique methodology positions Bio-Sourcing at the forefront of biopharmaceutical innovation, offering a potentially more efficient and cost-effective alternative to traditional production methods.
How much funding has Bio-Sourcing raised?
Bio-Sourcing has raised a total of $13.6M across 2 funding rounds:
Grant
$2.7M
Private Equity
$10.9M
Grant (2024): $2.7M with participation from The European Innovation Council
Private Equity (2024): $10.9M led by The European Innovation Council
Key Investors in Bio-Sourcing
The European Innovation Council
The European Innovation Council is an entity operating within the Colleges & Universities sector, focusing on fostering innovation and technological advancement. Its participation suggests a strategic interest in novel biotechnological platforms.
What's next for Bio-Sourcing?
With this major enterprise-level funding and strategic investment, Bio-Sourcing is poised for significant expansion and further development of its proprietary technology. The capital infusion is expected to accelerate the scaling of its production capabilities, enhance research and development efforts, and potentially broaden its market reach. This strategic financing signals strong confidence in Bio-Sourcing's business model and its potential to disrupt the biotherapeutics market, paving the way for future growth and the advancement of its pipeline.
See full Bio-Sourcing company page
